PharmaTher Seeks FDA Orphan Drug and Rare Pediatric Designations
PharmaTher submitted applications for orphan drug and rare pediatric disease designations for 3D-printed creatine monohydrate in GAMT deficiency. The program could qualify for a transferable priority review voucher.
Story updates
12:04:12 PM UTC
SquawkNews
PharmaTher filed FDA applications for Orphan Drug and Rare Pediatric Disease designations for 3D-printed creatine monohydrate to treat GAMT deficiency; FDA decisions and a pre-IND meeting are expected in Q1 2027.Material DetailsContext by AI AnalystThis is an early regulatory step signaling a pivot…